questions about Novedex

[PrairieDawg]

Does this stuff really work as a test booster? I've always thought of nolvadex as an anti e and didn't realize it boosted your test as well. So how much does this stuff really boost your test? The guy at the supp store was raving about it but I'm still not sold on it. Is Novedex just another fad? It has to be considerably weaker than the nolvadex I stacked with my cycle. I still have some of that left over in fact.

So if nolva really does boost your test considerably as well can I just use the shit I have left over from my cycle? I'd imagine it's the same thing only stronger right?

http://www.supplementscanada.com/pop...roduct616.html

[allpowerfull]

that stuff is crap 6-oxo works better but some real femoxtal NOVA generic im mexico i take it daily its even legal to cross did it today hahah

[T_man87]

An anti-E can help raise test somewhat. Lowering Estro generally will lead to a rise in test. Beyond that, I don't think it's a test booster. And BTW - I have used Novedex several times and liked it. ATD's seem to work good for me, however they still don't work as well as Arimidex . I also like Rebound XT from Anabolic Extreme and have stacked that with Novedex.

[Big]

Novedex and Nolvadex are 2 completely different things.

[AdamGH]

that stuff is crap 6-oxo works better but some real femoxtal NOVA generic im mexico i take it daily its even legal to cross did it today hahah

Here man, I edited best I could for you. I was limited on what I was working with though. So forgive me if their are errors.


"That stuff is crap! 6-oxo works way better in my opinion. Real femoxtal NOVA generic from Mexico is the best though. Definitely take it daily like me. I cross the US border with it all the time. I am so slick! hahah!"

[bulldawg_28]

Here are some studies on 6oxo, and novedex.

The purpose of this study was to determine the effects of 6-OXO, a purported nutritional
aromatase inhibitor, in a dose dependent manner on body composition, serum hormone levels, and
clinical safety markers in resistance trained males. Sixteen males were supplemented with either
300 mg or 600 mg of 6-OXO in a double-blind manner for eight weeks. Blood and urine samples
were obtained at weeks 0, 1, 3, 8, and 11 (after a 3-week washout period). Blood samples were
analyzed for total testosterone (TT), free testosterone (FT), dihydrotestosterone (DHT),
estradiol, estriol, estrone, SHBG, leutinizing hormone (LH), follicle stimulating hormone (FSH),
growth hormone (GH), cortisol, FT/estradiol (T/E). Blood and urine were also analyzed for clinical
chemistry markers. Data were analyzed with two-way MANOVA. For all of the serum hormones,
there were no significant differences between groups (p > 0.05). Compared to baseline, free
testosterone underwent overall increases of 90% for 300 mg 6-OXO and 84% for 600 mg,
respectively (p < 0.05). DHT underwent significant overall increases (p < 0.05) of 192% and 265%
with 300 mg and 600 mg, respectively. T/E increased 53% and 67% for 300 mg and 600 mg 6-OXO,
respectively. For estrone, 300 mg produced an overall increase of 22%, whereas 600 mg caused a
52% increase (p < 0.05). Body composition did not change with supplementation (p > 0.05) and
clinical safety markers were not adversely affected with ingestion of either supplement dose (p >
0.05). While neither of the 6-OXO dosages appears to have any negative effects on clinical
chemistry markers, supplementation at a daily dosage of 300 mg and 600 mg for eight weeks did
not completely inhibit aromatase activity, yet significantly increased FT, DHT, and T/E.

And here's he Novedex (ATD) study.

Novedex XT Clinical Trial
OHIO RESEARCH GROUP
Ziegenfuss T.N., Mendel R.W., and Hofheins J.E. Safety and Efficacy of a Naturally-Occurring, Orally Administered, Aromatase Inhibitor in Healthy Men. Ohio Research Group of Exercise Science and Sports Nutrition. Wadsworth, Ohio 44281, USA. [email protected]his email address is being protected from spam bots, you need Javascript enabled to view it

Rationale: In healthy men, it is known that blocking estrogen formation stimulates the HPT axis to increase in vivo testosterone production. Recently, a new class of dietary supplements has appeared that claim to inhibit the aromatase enzyme (i.e., decrease the transformation of aromatizable androgens [androstenedione, DHEA, testosterone] into estrogens [estriol, estrone, estradiol]), thus stimulating an increase in testosterone formation.

Purpose: The purpose of this pilot study was to examine the effects of a popular aromatase inhibitor, Novedex XTÔ (NOV-XT), on selected hormonal responses (total testosterone [TT], bioavailable testosterone [BT] and estradiol [E2]), as well as serum and plasma markers of renal, hepatic, and hematological function.

Methods: Using an open-label, proof-of-concept design, five eugonadal men (mean ± superdrol age, height, weight, body fat: 31.6 ± 2.8 yr, 174.3 ± 1.8 cm, 84.3 ± 3.8 kg, 11.2 ± 3.3 %) ingested 4 capsules of NOV-XT prior to bed for 28 consecutive days. According to the manufacturer, each capsule of NOV-XT contains 60 mg of a proprietary blend of three naturally-occurring aromatase inhibitors: 6, 17-keto-etiocholeve-3-ol tetrahydropyranol, 3, 17-keto-etiochol-triene, and 3’,5,7-trihydroxy-4’-methoxyflavone (supplements were provided by an FDA-registered, pharmaceutically licensed manufacturer; confirmation by an external laboratory is pending). Blood samples obtained at baseline (prior to supplementation), and at weekly intervals thereafter for 28 days, were analyzed for TT, BT, and E2 by radioimmunometric and chemilluminetric assays. Subjects were required to maintain their normal dietary and training patterns during the study. All blood samples were obtained at the same time of day (0700-0900) to minimize diurnal variation. Hormone concentrations were statistically analyzed by ANOVA and Tukey’s HSD post-hoc test. Dependent t-tests were used to compare changes in blood chemistries. Statistical significance was accepted at p<0.05.

Results: Compared to baseline, NOV-XT administration rapidly and significantly increased TT and BT. Mean changes from baseline for TT after one, two, three, and four weeks of NOV-XT administration were: +145% (p<0.006), +183% (p<0.0005), +232% (p<0.0002), and +240% (p<0.0002), respectively. Mean changes from baseline for BT after one, two, three, and four weeks of NOV-XT administration were: +300% (p<0.01), +402% (p<0.0009), +511% (p<0.0002), and +528% (p<0.0002), respectively. Despite these large increases in TT and BT, no significant aromatization to estradiol occurred (i.e., E2 concentrations remained unchanged). No significant changes in clinical blood chemistries (fasting glucose, BUN, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium, chloride, calcium, albumin, globulin, CO2, total protein, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol) or systemic hemodynamics (heart rate, systolic blood pressure, diastolic blood pressure) were observed, nor were any adverse events noted during the study.

Variable Baseline Day 7 Day 14 Day 21 Day 28
Testosterone (ng/dL) 517 (162) 1265 (252) * 1515 (212) * 1714 (322) * 1758 (435) *
Bio T (ng/dL) 159 (57) 636 (265) * 798 (94) * 971 (226) * 998 (210) *
Estradiol (pg/mL) 22 (3) 19 (9) 16 (9) 19 (11) 19 (9)
Glucose (mg/dL) 90 (4) 87 (10)
BUN:Cr 17 (5) 17 (4)
Bilirubin (mg/dL) 0.8 (0.5) 0.9 (0.5)
ALP (IU/L) 84 (32) 67 (43)
AST (IU/L) 27 (7) 27 (8)
ALT (IU/L) 29 (11) 31 (15)
Chol (mg/dL) 156 (19) 163 (27)
TAG (mg/dL) 74 (22) 72 (19)
HDL (mg/dL) 54 (3) 51 (9)
LDL (mg/dL) 87 (18) 97 (20)
SBP (mm Hg) 124 (5) 124 (11)
DBP (mm Hg) 75 (6) 74 (14)